Form 8-K - Current report:
SEC Accession No. 0000950170-25-032355
Filing Date
2025-03-04
Accepted
2025-03-04 17:00:08
Documents
11
Period of Report
2025-02-26
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20250226.htm   iXBRL 8-K 60732
  Complete submission text file 0000950170-25-032355.txt   185832

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20250226.xsd EX-101.SCH 32050
13 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20250226_htm.xml XML 4747
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 25705882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)